1:45 PM (PT)
-
Clinical trials in small populations, particularly those with progressive or degenerative rare diseases, face scientific and ethical hurdles that challenge traditional trial frameworks. High phenotypi ...Breakout Session 31C
3:00 PM (PT)
-
Clinical trials have too often failed to represent the communities they aim to serve - limiting the relevance, reach, and real‑world impact of medical innovation. The Robert A. Winn Excellence in Clin ...Breakout Session 26AB
4:15 PM (PT)
-
Congress created the Rare Pediatric Disease Priority Review Voucher (PRV) program to incentivize the development of drugs for serious or life-threatening rare diseases in children. Vouchers are earned ...Breakout Session 30DE
-
We are living in a golden age of biopharmaceutical innovation. Yet, too often, patients face barriers between them and the appropriate treatment they need across various cost-shifting programs. Payers ...Breakout Session 29C
1:45 PM (PT)
-
In recent years, a confluence of global economic, market, and policy shifts have led to the abandonment of more than 1,000 promising treatments in development for rare diseases - many of which deliver ...Breakout Session 25ABC
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}